Last reviewed · How we verify
Malignant lymphoma, large B-cell, diffuse
Approved treatments
- Xmab5574 · Morphosys Us Inc
Tafasitamab works by binding to the CD19 antigen on B-lymphocytes, triggering an immune response against cancer cells. - MONJUVI · MORPHOSYS US INC
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Malignant lymphoma, large B-cell, diffuse patent landscape — cliff calendar, originator estates, attackable patents
- Malignant lymphoma, large B-cell, diffuse treatment landscape brief
- Malignant lymphoma, large B-cell, diffuse treatment updates RSS
Frequently asked questions about Malignant lymphoma, large B-cell, diffuse
What drugs treat Malignant lymphoma, large B-cell, diffuse?
Tracked treatments include Xmab5574, MONJUVI.
What is the treatment for Malignant lymphoma, large B-cell, diffuse?
Standard treatment for Malignant lymphoma, large B-cell, diffuse includes Xmab5574, MONJUVI. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Malignant lymphoma, large B-cell, diffuse patent cliff · Malignant lymphoma, large B-cell, diffuse CI report
- Treatment: Xmab5574 · Morphosys Us Inc
- Treatment: MONJUVI · MORPHOSYS US INC
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing